C4 glomerulopathy Medical therapy: Difference between revisions
Jump to navigation
Jump to search
Tarek Nafee (talk | contribs) (Created page with "__NOTOC__ {{C4 glomerulopathy}} {{CMG}}; {{APM}}; {{AE}} {{OO}} ==Overview== ==Medical Therapy== ==References== {{Reflist|2}} {{WH}}{{WS}}") |
Norina Usman (talk | contribs) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The mainstay of treatment for C4 glomerulopathy is antihypertensive and lipid-lowering drugs. | |||
==Medical Therapy== | ==Medical Therapy== | ||
Pharmacologic medical therapies for C4 glomerulopathy include<ref name="AppelCook2005">{{cite journal|last1=Appel|first1=Gerald B.|last2=Cook|first2=H. Terence|last3=Hageman|first3=Gregory|last4=Jennette|first4=J. Charles|last5=Kashgarian|first5=Michael|last6=Kirschfink|first6=Michael|last7=Lambris|first7=John D.|last8=Lanning|first8=Lynne|last9=Lutz|first9=Hans U.|last10=Meri|first10=Seppo|last11=Rose|first11=Noel R.|last12=Salant|first12=David J.|last13=Sethi|first13=Sanjeev|last14=Smith|first14=Richard J.H.|last15=Smoyer|first15=William|last16=Tully|first16=Hope F.|last17=Tully|first17=Sean P.|last18=Walker|first18=Patrick|last19=Welsh|first19=Michael|last20=Würzner|first20=Reinhard|last21=Zipfel|first21=Peter F.|title=Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update|journal=Journal of the American Society of Nephrology|volume=16|issue=5|year=2005|pages=1392–1403|issn=1046-6673|doi=10.1681/ASN.2005010078}}</ref><ref name="AliSchlanger2016">{{cite journal|last1=Ali|first1=Arshad|last2=Schlanger|first2=Lynn|last3=Nasr|first3=Samih H.|last4=Sethi|first4=Sanjeev|last5=Gorbatkin|first5=Steven M.|title=Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure|journal=American Journal of Kidney Diseases|volume=67|issue=3|year=2016|pages=479–482|issn=02726386|doi=10.1053/j.ajkd.2015.10.020}}</ref>: | |||
*Lipid-lowering drugs | |||
*Antihypertensive drugs | |||
**ACE-inhibitors | |||
**Angiotensin-II inhibitors | |||
*Immunosuppressive therapy | |||
==References== | ==References== | ||
Latest revision as of 17:05, 8 August 2020
|
C4 glomerulopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
C4 glomerulopathy Medical therapy On the Web |
|
American Roentgen Ray Society Images of C4 glomerulopathy Medical therapy |
|
Risk calculators and risk factors for C4 glomerulopathy Medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]
Overview
The mainstay of treatment for C4 glomerulopathy is antihypertensive and lipid-lowering drugs.
Medical Therapy
Pharmacologic medical therapies for C4 glomerulopathy include[1][2]:
- Lipid-lowering drugs
- Antihypertensive drugs
- ACE-inhibitors
- Angiotensin-II inhibitors
- Immunosuppressive therapy
References
- ↑ Appel, Gerald B.; Cook, H. Terence; Hageman, Gregory; Jennette, J. Charles; Kashgarian, Michael; Kirschfink, Michael; Lambris, John D.; Lanning, Lynne; Lutz, Hans U.; Meri, Seppo; Rose, Noel R.; Salant, David J.; Sethi, Sanjeev; Smith, Richard J.H.; Smoyer, William; Tully, Hope F.; Tully, Sean P.; Walker, Patrick; Welsh, Michael; Würzner, Reinhard; Zipfel, Peter F. (2005). "Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update". Journal of the American Society of Nephrology. 16 (5): 1392–1403. doi:10.1681/ASN.2005010078. ISSN 1046-6673.
- ↑ Ali, Arshad; Schlanger, Lynn; Nasr, Samih H.; Sethi, Sanjeev; Gorbatkin, Steven M. (2016). "Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure". American Journal of Kidney Diseases. 67 (3): 479–482. doi:10.1053/j.ajkd.2015.10.020. ISSN 0272-6386.